Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Nissei Bio provides raw materials that have been researched and developed. It manufactures and sale of raw materials and materials for health foods, cosmetics, hair restorers, and other related products. It was established on September 14, 1994.

Integrated DNA Technologies sells short strands of DNA called oligonucleotides. In order to better understand how these are useful, you'll have to know a bit about DNA itself. DNA is "the blueprint for life" and encodes instructions for all of life's processes. DNA is a complex long thin molecule (strand) that is made from 4 possible building blocks called "bases". These bases are called Adenine, Cytosine, Guanine and Thymine, and the precise order of these bases is a code for information. In living organisms, DNA strands can be millions of bases long and therefore contain huge amounts of information. This complexity is responsible for the vast complexity and diversity of life on earth. The way that one strand of DNA specifically binds a second strand of DNA allows scientists to use short DNA strands (oligos) as research tools. A short synthetic piece of DNA (usually around 20 bases long) can be used to bind or find its matching sequence even in a complex mixture of millions of unrelated pieces of DNA. It is this unique fact that allows researchers to decode and study the genetic makeup of any living organism. Using new oligo-based technologies, a revolution is underway where they are beginning to catalog the complete genetic makeup of hundreds of living things, ranging from bacteria to humans. The human genome alone contains over 3 billion bases of DNA, so projects of this kind tend to be very complex and often take years to complete. Scientists often start the research knowing the DNA sequence for the organism that they are interested in studying. Given a known DNA sequence, they can easily design a short oligo that can be used to perform a variety of tasks. It is this short single-stranded DNA that the researcher orders from IDT. Living systems don't discriminate DNA that is synthesized chemically from DNA taken directly from an organism, allowing researchers to use IDT's custom made oligonucleotides as if they had existed naturally. IDT manufactures the oligo using chemical DNA synthesis machines designed and built in-house. They've refined the process to the point where they can receive an order as late as 1:00pm and have the desired oligo in the researcher's hands the next morning. Their customers range from small university labs of only a few scientists to global pharmaceutical companies, and everything in between.

TargetGene is developing cell-therapies for Immune-disorders, Cancer and Genetic diseases. We have developed an efficient and versatile ultra-precise dual-RNA guided genome-editing platform, T-GEE, which is orders of magnitude more precise than CRISPR, solving the off-target problem and potentially creating a radically safer tool. T-GEE can permanently modify the patient’s own DNA, whereby genes can be deleted, replaced or added in specific cells, allowing cures as opposed to chronic treatment. TargetGene has identified several diseases, including orphan and major diseases, where a simple alteration of a gene in patient-extracted immune cells (ex-vivo), will provide a cure. Thus, we are seeking to fund our pre-clinical pipeline and accelerate T-GEE’s trajectory to become the dominant genome editing system it deserves to be.

The Research Institute at Nationwide Children's Hospital is one of America's ten largest free-standing pediatric research centers and works to enhance the health of children by engaging in research.

Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Shanghai Bode Gene Development Co., Ltd., established on 1998-03-22, Business scope includes bioengineering,Technology transfer in the field of genetic engineering expertise,technology development,technical consulting,Technical services and manufacture of related reagents and equipment,Sales;Bioengineering and Genetic Engineering Products,electronics,Chemical Products(In addition to dangerous goods)import and export business. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Intervet International BV engages in the manufacture and marketing of animal health products. It offers vaccines, anti-infectives, anti-parasitics, feed additives and products for fertility management. The firm products are used for treatment and care of poultry, pigs, cattle, sheep, goats, horses, fish, shrimp and companion animals. The company was founded by Wim Hendrix in 1949 and is headquartered in Boxmeer, the Netherlands.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

VGX Pharmaceuticals LLC develops pharmaceuticals. The company was founded by J. Joseph Kim and is headquartered in Blue Bell, PA.

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.